TABLE 2.

Cross-reactivity of WNV NS5 and E protein with DEN patient sera

Samplea	MFI		Titer
	NS5b	E proteinc	E protein MIAd	HI
1A	1,225	280	<100	10
1B	1,368	2,016	200	160
2A	2,325	1,440	100	20
2B	2,614	2,951	400	80
3A	5,677	6,587	25,600	10,240
3B	2,472	4,894	3,200	320
4A	1,348	180	<100	−
4B	5,750	1,554	200	640
5A	674	235	<100	−
5B	715	1,497	200	40
6A	810	113	<100	−
6B	953	1,081	100	160
7A	2,432	289	<100	−
7B	4,935	2,860	100	80
8A	720	875	<100	20
8B	829	558	<100	80
9A	864	3,459	400	160
9B	1,864	4,826	1600	160
10A	1,832	1,366	100	20
10B	1,755	6,686	6,400	10,240
11A	4,658	7,474	51,200	10,240
11B	1,723	5,013	6,400	1,280
12A	841	5,344	3200	640
12B	794	6,105	12,800	2,560
13A	3,833	825	100	80
13B	2,761	1,549	800	80
14A	678	5,578	6400	2,560
14B	757	4,720	1600	80
15A	1,548	4,807	1600	160
15B	1,587	8,626	51,200	10,240
16A	945	6,159	3,200	640
16B	1,128	6,417	6,400	80
17A	1,427	225	<100	−
17B	1,554	3,108	800	800

^aSeventeen pairs of acute-phase (A) and convalescent-phase (B) sera from DEN-infected individuals were tested.

^bThe cutoff for positivity for NS5 is 4,366. There were 3 positive samples out of 34 (8.8%).

^cThe cutoff for positivity for E protein is 1,084 (Wong et al., submitted). There were 24 positive samples out of 34 (71%).

^dE protein MIA titers represent the maximal dilutions of patient sera that were reactive in the E-protein-based MIA above the MFI cutoff of 1,084.